Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For men with advanced prostate cancer (mCRPC):

• Men who have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed by lab testing, but not the pure small cell type.
• Men whose PSA level is at least 4 ng/mL at the screening visit and has been rising in the 6 months before screening.
• Men who have already received at least 2 previous approved treatments for their prostate cancer (beyond hormone-blocking therapy), including at least one newer anti-hormone drug (such as abiraterone, enzalutamide, apalutamide, or darolutamide) AND a specific type of radiation therapy targeting PSMA (such as 177Lu-PSMA-617).

For men and women with advanced kidney cancer (ccRCC):

• People who have been diagnosed with a specific type of kidney cancer called clear-cell renal cell carcinoma, confirmed by lab testing.
• People whose kidney cancer has spread to other parts of the body and has at least one measurable tumour spot on scans.
• People who have already received at least one approved treatment for their advanced kidney cancer, which must have included an immunotherapy drug targeting PD-1 or PD-L1, and either ipilimumab or a targeted therapy drug called a tyrosine kinase inhibitor.

Who may not be able to join:

• People who received an approved cancer treatment within 3 weeks before the first study dose, or who are still experiencing side effects from a previous treatment.
• People who received a biological cancer therapy within a certain time window before the first study dose (confirm specific timing with trial site).
• People who have previously received any therapy that targets PSMA — except for a PSMA-targeted radiation treatment (such as 177Lu-PSMA-617) in the prostate cancer group.
• People in the dose escalation phase who have had prior immunotherapy cancer treatment (other than a specific vaccine called sipuleucel-T) within a certain time before the study.
• People in the dose expansion phase (prostate cancer group only) who have had any prior immunotherapy cancer treatment.
• People who need ongoing daily use of corticosteroid medicines above a certain dose (more than 10 mg of prednisone per day or an equivalent anti-inflammatory drug) within 1 week before the first study dose.
• People who have had a significant autoimmune disease in the past 5 years that required treatment with medicines that suppress the immune system.
• People who have had brain inflammation (encephalitis), meningitis, a progressive neurological disease (except mild memory problems that do not affect daily life), or poorly controlled seizures in the year before the first study dose.
• People with an uncontrolled HIV, hepatitis B, or hepatitis C infection, or a diagnosed immune system deficiency.

Important: Always verify eligibility with the trial site directly before applying.